SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma rises as its arm plan to acquire Thallion Pharmaceuticals

20 Mar 2017 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 708.55, up by 1.85 points or 0.26% from its previous closing of Rs. 706.70 on the BSE.

The scrip opened at Rs. 708.00 and has touched a high and low of Rs. 711.50 and Rs. 705.25 respectively. So far 78525 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 854.50 on 05-Aug-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 728.45 and Rs. 678.10 respectively. The current market cap of the company is Rs. 169977.78 crore.

The promoters holding in the company stood at 54.39%, while Institutions and Non-Institutions held 33.97% and 11.65% respectively.

Taro Pharmaceuticals (Canada), an indirect subsidiary of Sun Pharmaceutical Industries, has entered into an agreement to acquire all of the issued and outstanding shares of Thallion Pharmaceuticals, a Canadian pharmaceutical corporation. Post the acquisition of Thallion Pharmaceutical, Taro Pharmaceuticals would have only rights for development of orphan drug candidate, Shigamab, which targets E. Coli-induced hemolytic-uremic syndrome.

Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.

 

Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×